Cohort studyindependent cross-checkabstract only checked★ key study I-INS-04 in-depth review
How much long-term blood sugar matters (UKPDS 35)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
Overview
Stratton IM et al.. BMJ 2000 · PMID 10938048 · DOI 10.1136/bmj.321.7258.405
Each 1% lower HbA1c was linked to 21% fewer diabetes deaths and 37% fewer eye/kidney complications.
Does the study support the specific claim? No · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Relation of glycaemia over time to complications
- How was the study done?
Prospective observational analysis within UKPDS (UKPDS 35)
- How many people, animals or samples were studied?
4,585 (3,642 for RR); UKPDS patients (white, Asian Indian, Afro-Caribbean)
- What was actually found?
Graded risk with HbA1c, no threshold.
- How large was the observed effect?
-21% per 1% HbA1c
- What do the results mean in everyday life?
High sugar damages the body.
- What are the study's limitations?
Observational
- What does it say about Elawady's specific claim?
Contradicts C-DIAB-01, C-DIAB-02, C-ODD-06 (hyperglycaemia causes complications incl. amputation).
- Do the results apply to Germany and Europe?
UK.
- What can explicitly not be concluded from this study?
That pushing HbA1c to normal is always safe.
Scientific in-depth review
1. Full reference
- Authors
- Stratton IM et al.
- Journal
- BMJ
- Year
- 2000
- Identifier
- PMID 10938048 DOI 10.1136/bmj.321.7258.405
- Verification
- verified – PubMed efetch 2026-10-25 (this agent)
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
Relation of glycaemia over time to complications
3. Study design and population
- Study design
- Cohort study – Prospective observational analysis within UKPDS (UKPDS 35)
- Population
UKPDS patients (white, Asian Indian, Afro-Caribbean)
- Country
UK
- Period
UKPDS duration
- Sample size
4,585 (3,642 for RR)
- Inclusion and exclusion criteria
As described in the abstract; details not available in abstract.
4. Methods and endpoints
- Exposure / intervention
Updated mean HbA1c
- Comparator
Per 1% lower HbA1c
- Endpoints
Diabetes-related endpoints, death, MI, stroke, amputation, microvascular
- Statistical methods
Poisson/Cox adjusted
5. Actual results
- Results
Per 1% HbA1c reduction: any diabetes endpoint -21% (17-24%), diabetes-related death -21% (15-27%), MI -14% (8-21%), microvascular -37% (33-41%); no threshold.
- Absolute risks
not reported
- Authors' conclusion
Risk of complications strongly associated with previous hyperglycaemia; any HbA1c reduction likely reduces risk, lowest risk in normal range.
6. Strengths
- Large prospective dataset
- Repeated HbA1c
7. Weaknesses
- Observational
8. Risk of bias
- Orienting tool
- ROBINS-E
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Observational association.
9. Assessment of the statistical interpretation
Strong graded association.
10. Relevance to the specific claim
Contradicts C-DIAB-01, C-DIAB-02, C-ODD-06 (hyperglycaemia causes complications incl. amputation).
11. Independent contrary findings
ACCORD for extreme targets.
12. Transferability to Germany and Europe
UK.
13. Overall methodological judgement
Strong epidemiological evidence that high glucose is harmful.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | high |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
None beyond those stated.
15. Linked fact checks
- Insulin is not needed for glucose to enter cells (the HbA1c inside red blood cells proves it); insulin therefore does not treat diabetes but 'starves' cells, especially the brain, of sugar. – Studies contradicting or limiting the claim
- Glucose-lowering drugs are net harmful and belong among the 'forbidden' items; dapagliflozin (Forxiga) is among the 'dirtiest' drugs and kills the brain; leg amputations happen only to people taking diabetes drugs and insulin. – Studies contradicting or limiting the claim
- High blood sugar is not a disease but the body's protective response that 'rescues' you; there is no such thing as diabetes ('drink sugar'); sugar intake has no upper limit; HbA1c is a lie. – Studies contradicting or limiting the claim
- Laboratory values such as blood glucose and acetone are only signs of the body's changing strategy and not causes; there is no need to measure glucose or blood pressure. – Studies contradicting or limiting the claim